BioAge Labs, Inc (BIOA) - Net Assets
Based on the latest financial reports, BioAge Labs, Inc (BIOA) has net assets worth $277.46 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($305.09 Million) and total liabilities ($27.63 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of BioAge Labs, Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $277.46 Million |
| % of Total Assets | 90.94% |
| Annual Growth Rate | 15.69% |
| 5-Year Change | 566.37% |
| 10-Year Change | N/A |
| Growth Volatility | 238.7 |
BioAge Labs, Inc - Net Assets Trend (2013–2024)
This chart illustrates how BioAge Labs, Inc's net assets have evolved over time, based on quarterly financial data. Also explore BIOA asset base for the complete picture of this company's asset base.
Annual Net Assets for BioAge Labs, Inc (2013–2024)
The table below shows the annual net assets of BioAge Labs, Inc from 2013 to 2024. For live valuation and market cap data, see BIOA company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $323.13 Million | +286.35% |
| 2023-12-31 | $-173.40 Million | -54.05% |
| 2022-12-31 | $-112.56 Million | -615.08% |
| 2017-12-31 | $21.85 Million | -54.93% |
| 2016-12-31 | $48.49 Million | +4.61% |
| 2015-12-31 | $46.36 Million | -19.42% |
| 2014-12-31 | $57.53 Million | -11.50% |
| 2013-12-31 | $65.01 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioAge Labs, Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13776705000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $245.00K | 0.08% |
| Other Components | $575.69 Million | 178.16% |
| Total Equity | $323.13 Million | 100.00% |
BioAge Labs, Inc Competitors by Market Cap
The table below lists competitors of BioAge Labs, Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Clevo Co
TW:2362
|
$701.09 Million |
|
Telesat Corp
TO:TSAT
|
$701.13 Million |
|
Velesto Energy Bhd
KLSE:5243
|
$701.31 Million |
|
Gan Yuan Foods Co Ltd
SHE:002991
|
$701.53 Million |
|
Beijing Career International Co Ltd
SHE:300662
|
$700.97 Million |
|
Citycon Oyj
HE:CTY1S
|
$700.87 Million |
|
PSI Software AG
F:PSAN
|
$700.76 Million |
|
Kingfa Science & Technology (India) Limited
NSE:KINGFA
|
$700.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioAge Labs, Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -173,396,000 to 323,127,000, a change of 496,523,000.
- Net loss of 71,109,000 reduced equity.
- New share issuances of 391,619,000 increased equity.
- Other comprehensive income increased equity by 81,000.
- Other factors increased equity by 175,932,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-71.11 Million | -22.01% |
| Share Issuances | $391.62 Million | +121.2% |
| Other Comprehensive Income | $81.00K | +0.03% |
| Other Changes | $175.93 Million | +54.45% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares BioAge Labs, Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.56x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 7.28x to 0.56x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $2.31 | $16.79 | x |
| 2014-12-31 | $2.04 | $16.79 | x |
| 2015-12-31 | $1.64 | $16.79 | x |
| 2016-12-31 | $1.42 | $16.79 | x |
| 2017-12-31 | $0.52 | $16.79 | x |
| 2022-12-31 | $-15.09 | $16.79 | x |
| 2023-12-31 | $-23.23 | $16.79 | x |
| 2024-12-31 | $30.12 | $16.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioAge Labs, Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -22.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.11x
- Recent ROE (-22.01%) is above the historical average (-91.20%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -51.10% | -1246.33% | 0.02x | 1.75x | $-39.72 Million |
| 2014 | -80.69% | -3008.45% | 0.01x | 2.65x | $-52.17 Million |
| 2015 | -80.31% | -1713.94% | 0.02x | 3.09x | $-41.86 Million |
| 2016 | -46.36% | -271.72% | 0.05x | 3.33x | $-27.33 Million |
| 2017 | -449.15% | -656.84% | 0.21x | 3.18x | $-100.34 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-28.47 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-46.51 Million |
| 2024 | -22.01% | 0.00% | 0.00x | 1.11x | $-103.42 Million |
Industry Comparison
This section compares BioAge Labs, Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $236,113,024
- Average return on equity (ROE) among peers: -47.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioAge Labs, Inc (BIOA) | $277.46 Million | -51.10% | 0.10x | $701.02 Million |
| Aurora Cannabis Inc (ACB) | $602.92 Million | -11.50% | 0.39x | $197.35 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $54.20 Million | -73.99% | 0.03x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $1.77 Billion |
| Amphastar P (AMPH) | $639.42 Million | 21.51% | 1.37x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -104.36% | 9.57x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $344.93 Million | 26.40% | 10.61x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $40.96 Million | 0.73% | 0.09x | $1.80 Billion |
About BioAge Labs, Inc
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. It also provides azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment o… Read more